Investor Presentaiton

Wave 2 Dual targeting BCMAXGPRC5D CART for relapsed/refractory multiple myeloma Transformational potential Primary and secondary non-response to standard of care therapies remains an unmet medical need in MM. Surface BCMA expression Causal human biology BCMA and GPRC5D are clinically validated targets independently expressed in multiple myeloma Antigen heterogeneity and clonal evolution are factors limiting efficacy of BCMA CAR T in multiple myeloma 40000 20000 10000 6000 4000 2000 1000 600 400 200 100 High BCMA Low GPRC5D 100 Low BCMA High GPRC5D 400 1000 4000 10000 40000 % BCMA positive tumor cells 1201 100- 80- Abecma trial 0 0 0 0 0 0 0 0 0 0 0 000000000000 Oooo 60- 0 هلم 40- 20- 0 000 ° ° ° . Matching modality to mechanism Optimized bispecific construct to overcome intra-and inter-patient antigen variability/heterogeneity and maintain functionality in cases of low BCMA Optimized manufacturing to develop at scale process improving product quality and manufacturing failures Myeloma burden (SBCMA) Path to clinical proof-of-concept Non-response Early relapse (3-6M) CART Infusion Getting into Depth of initial Maintaining response response response Loss of functional CAR T Late relapse Surface GPRC5D expression Ill Bristol Myers Squibb™ Baseline Biopsy Progression Biopsy Not for Product Promotional Use 46

View entire presentation